Side-by-side comparison of AI visibility scores, market position, and capabilities
Alumis is a clinical-stage biopharmaceutical company developing oral TYK2 inhibitors for immune-mediated diseases including psoriasis, lupus, and inflammatory bowel disease; raised over $400M in private funding;
Alumis is a South San Francisco-based clinical-stage biopharmaceutical company founded in 2021 by Martin Babler and Joseph Arol, with a focus on developing precision oral therapies for patients with serious immune-mediated diseases. The company's lead program, ESK-001, is a highly selective TYK2 (tyrosine kinase 2) inhibitor targeting conditions including moderate-to-severe plaque psoriasis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. TYK2 inhibition is a validated immunology mechanism — Bristol Myers Squibb's Sotyktu (deucravacitinib) was the first approved TYK2 inhibitor — and Alumis is developing what it believes is a next-generation molecule with improved selectivity.
DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I led by Blackstone Growth; serves 7 of top 10 pharma and 8 of top 10 diagnostics companies.
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a secure, scalable, and regulatory-compliant cloud environment where pharmaceutical companies, genomics labs, biobanks, health systems, and research institutions can store, analyze, and share multimodal biomedical data — including genomic sequences, clinical records, imaging, and real-world evidence. The platform is purpose-built for the data types, compliance requirements, and computational workloads unique to biomedical research and precision medicine development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.